GRIK4 rs1954787 基因多态性与抗抑郁药治疗抑郁症患者临床缓解的关联:前瞻性队列与荟萃分析结果
在 METADAP 队列 390 例接受 6 个月抗抑郁药治疗的抑郁症患者中,分析 GRIK4 rs1954787(T>C) 多态性与汉密尔顿抑郁量表评分及缓解率的关联,并结合既往数据做荟萃分析。结果提示该多态性与抗抑郁药治疗后的临床改善相关,作者认为需在其他纵向研究中进一步评估。
要点
- 治疗 3 个月时,TT 纯合子较 C 等位基因携带者 HDRS 评分更高、缓解率更低。
- 治疗 6 个月时,TT 纯合子与 C 等位基因携带者间 HDRS 评分与缓解率差异更大。
- 荟萃分析显示 C 等位基因与抗抑郁药治疗反应相关。
核心结论
- 结果支持 GRIK4 rs1954787(T>C) 多态性与抗抑郁药治疗后的临床改善存在关联,该关联需在其他纵向研究中进一步评估。
研究设计与样本
- 研究纳入 METADAP 队列 390 例接受抗抑郁药治疗的患者,在基线及治疗 1、3、6 个月时采集临床数据,采用混合效应模型分析多态性与 HDRS 评分及反应率、缓解率的关联,并开展抗抑郁药治疗反应的荟萃分析。
主要发现
- 治疗 3 个月时,TT 纯合子(n=66)较 C 等位基因携带者(n=200)HDRS 评分更高(系数=3.37,95%CI [1.30-5.54],Padj=0.0046)、缓解率更低(OR=0.36,95%CI [0.16-0.76],Padj=0.029)。
- 治疗 6 个月时,TT 纯合子(n=53)与 C 等位基因携带者(n=152)间 HDRS 评分差异更大(系数=4.68,95%CI [2.17-7.18],Padj=0.00091),缓解率差异也更大(OR=0.26,95%CI [0.12-0.54],Padj=0.0016)。
- 荟萃分析中,C 与 T 等位基因比较的反应率差异有统计学意义(OR=1.31,95%CI [1.06-1.62],P=0.014),CC 与 TT 基因型比较亦有统计学意义(OR=1.63,95%CI [1.10-2.38],P=0.019)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出该关联需在其他纵向研究中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others. We aimed to analyze its association with clinical outcomes in a cohort of 6-month ATD-treated patients and meta-analysis. Clinical data were obtained at baseline and after 1 (M1), 3 (M3), and 6 (M6) months of ATD treatment in 390 patients of the METADAP cohort. Mixed-effects models were used to assess the association of the GRIK4 rs1954787 polymorphism with the Hamilton Depression Rating Scale (HDRS) score and response and remission rates across time. Meta-analyses of ATD treatment response were performed with previously meta-analyzed data and METADAP. Compared to C allele carriers at M3 (n = 200), TT homozygotes at M3 (n = 66) had higher HDRS scores (coef = 3.37, 95% CI [1.30-5.54], Padj = 0.0046) and lower remission rates (OR = 0.36, 95% CI [0.16-0.76], Padj = 0.029). At M6, greater differences between TT homozygotes (n = 53) and C allele carriers (n = 152) were observed for HDRS scores (coef = 4.68, 95% CI [2.17-7.18], Padj = 0.00091) and remission rates (OR = 0.26, 95% CI [0.12-0.54], Padj = 0.0016). Meta-analyses of response were significant when comparing C vs T alleles (OR = 1.31, 95% CI [1.06-1.62], P = 0.014) and CC vs TT genotypes (OR = 1.63, 95% CI [1.10-2.38], P = 0.019). Altogether, our results support an association of the GRIK4 rs1954787(T>C) polymorphism with clinical improvement following ATD treatment. This association should be further assessed in other longitudinal studies. Its position within the glutamatergic system may help in understanding the mechanism of ATD action.
引用
- Chappell K, Colle R, El Asmar K, et al. Association of the GRIK4 rs1954787 polymorphism with clinical response in antidepressant-treated depressed patients: results from a prospective cohort and meta-analysis. Mol Psychiatry. 2024. PMID: 39462036. doi:10.1038/s41380-024-02765-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。